<SEC-DOCUMENT>0001437749-25-030719.txt : 20251008
<SEC-HEADER>0001437749-25-030719.hdr.sgml : 20251008
<ACCEPTANCE-DATETIME>20251008163330
ACCESSION NUMBER:		0001437749-25-030719
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		15
CONFORMED PERIOD OF REPORT:	20251008
ITEM INFORMATION:		Regulation FD Disclosure
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20251008
DATE AS OF CHANGE:		20251008

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			CervoMed Inc.
		CENTRAL INDEX KEY:			0001053691
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				300645032
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-37942
		FILM NUMBER:		251382678

	BUSINESS ADDRESS:	
		STREET 1:		20 PARK PLAZA
		STREET 2:		SUITE 424
		CITY:			BOSTON
		STATE:			MA
		ZIP:			02116
		BUSINESS PHONE:		(617) 744-4400

	MAIL ADDRESS:	
		STREET 1:		20 PARK PLAZA
		STREET 2:		SUITE 424
		CITY:			BOSTON
		STATE:			MA
		ZIP:			02116

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Diffusion Pharmaceuticals Inc.
		DATE OF NAME CHANGE:	20160115

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	RestorGenex Corp
		DATE OF NAME CHANGE:	20140307

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Stratus Media Group, Inc
		DATE OF NAME CHANGE:	20080722
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>crvo20251008_8k.htm
<DESCRIPTION>FORM 8-K
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:naics="http://xbrl.sec.gov/naics/2024" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xsd="http://www.w3.org/2001/XMLSchema" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:us-types="http://fasb.org/us-types/2024" xmlns:utreg="http://www.xbrl.org/2009/utr" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:us-roles="http://fasb.org/us-roles/2020-01-31" xmlns:stpr="http://xbrl.sec.gov/stpr/2024" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:thunderdome="http://www.RDGFilings.com" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:dei="http://xbrl.sec.gov/dei/2024" xmlns:us-gaap="http://fasb.org/us-gaap/2024" xmlns:country="http://xbrl.sec.gov/country/2024" xmlns:rr="http://xbrl.sec.gov/rr/2018-01-31" xmlns:sic="http://xbrl.sec.gov/sic/2024" xmlns:currency="http://xbrl.sec.gov/currency/2024" xmlns:exch="http://xbrl.sec.gov/exch/2024" xmlns:srt="http://fasb.org/srt/2024" xmlns:cyd="http://xbrl.sec.gov/cyd/2024" xmlns:crvo="http://www.crvo.com/20251008"><head>
	<title>crvo20251008_8k.htm</title>

	<!-- Generated by ThunderDome Portal - 10/8/2025 6:56:57 PM -->
<meta http-equiv="Content-Type" content="text/html"/></head>
<body style="font-size:10pt;font-family:'Times New Roman';padding:0in .1in;"><div style="display: none">
<ix:header>
<ix:hidden>
<ix:nonNumeric contextRef="d20258K" name="dei:AmendmentFlag" id="ixv-300">false</ix:nonNumeric>
<ix:nonNumeric contextRef="d20258K" name="dei:EntityCentralIndexKey" id="ixv-301">0001053691</ix:nonNumeric>

</ix:hidden>
<ix:references>
<link:schemaRef xlink:href="crvo-20251008.xsd" xlink:type="simple"/>
</ix:references>
<ix:resources>
<xbrli:context id="d20258K">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001053691</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2025-10-08</xbrli:startDate>
<xbrli:endDate>2025-10-08</xbrli:endDate>
</xbrli:period>
</xbrli:context>



</ix:resources>
</ix:header>
</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<hr style="height: 3px; color: #000000; background-color: #000000; width: 100%; border: none; margin: 3pt 0"/>
<hr style="height: 1px; color: #000000; background-color: #000000; width: 100%; border: none; margin: 0 0 3pt 0"/>
<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family:Times New Roman;font-size:18pt;font-variant:normal;text-align:center;margin:0pt;"><b>UNITED STATES</b></div>

<div style="font-family:Times New Roman;font-size:18pt;font-variant:normal;text-align:center;margin:0pt;"><b>SECURITIES AND EXCHANGE COMMISSION</b></div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Washington, D.C. 20549</b></div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<hr style="text-align: center; height: 1px; color: #000000; background-color: #000000; width: 25%; border: none; margin: 3pt auto"/>
<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family:Times New Roman;font-size:18pt;font-variant:normal;text-align:center;margin:0pt;"><b>FORM <ix:nonNumeric contextRef="d20258K" name="dei:DocumentType" id="ixv-311">8-K</ix:nonNumeric></b></div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<hr style="text-align: center; height: 1px; color: #000000; background-color: #000000; width: 25%; border: none; margin: 3pt auto"/>
<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>CURRENT REPORT</b></div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Pursuant to Section 13 or 15(d)</b></div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>of The Securities Exchange Act of 1934</b></div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><ix:nonNumeric contextRef="d20258K" format="ixt:datemonthdayyearen" name="dei:DocumentPeriodEndDate" id="ixv-312">October 8, 2025</ix:nonNumeric></b></div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Date of Report (Date of earliest event reported)</b></div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<hr style="text-align: center; height: 1px; color: #000000; background-color: #000000; width: 25%; border: none; margin: 3pt auto"/>
<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family:Times New Roman;font-size:24pt;font-variant:normal;text-align:center;margin:0pt;"><b><ix:nonNumeric contextRef="d20258K" name="dei:EntityRegistrantName" id="ixv-313">CervoMed Inc.</ix:nonNumeric></b></div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>(Exact name of registrant as specified in its charter)</b></div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<hr style="text-align: center; height: 1px; color: #000000; background-color: #000000; width: 25%; border: none; margin: 3pt auto"/>
<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tbody><tr>
			<td style="vertical-align:top;width:15.3%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><ix:nonNumeric contextRef="d20258K" format="ixt-sec:stateprovnameen" name="dei:EntityIncorporationStateCountryCode" id="ixv-314">Delaware</ix:nonNumeric></b></div>
			</td>
			<td style="vertical-align:top;width:15.7%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><ix:nonNumeric contextRef="d20258K" name="dei:EntityFileNumber" id="ixv-315">001-37942</ix:nonNumeric></b></div>
			</td>
			<td style="vertical-align:top;width:15.3%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><ix:nonNumeric contextRef="d20258K" name="dei:EntityTaxIdentificationNumber" id="ixv-316">30-0645032</ix:nonNumeric></b></div>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:15.3%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>(State or other jurisdiction</b></div>

			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>of incorporation)</b></div>
			</td>
			<td style="vertical-align:top;width:15.7%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>(Commission</b></div>

			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>File Number)</b></div>
			</td>
			<td style="vertical-align:top;width:15.3%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>(I.R.S. Employer</b></div>

			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Identification No.)</b></div>
			</td>
		</tr>
		<tr>
			<td colspan="2" style="vertical-align:middle;width:15.3%;">&#160;</td>
			<td style="vertical-align:middle;width:15.3%;">&#160;</td>
		</tr>
		<tr>
			<td colspan="2" style="vertical-align:top;width:15.3%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><ix:nonNumeric contextRef="d20258K" name="dei:EntityAddressAddressLine1" id="ixv-317">20 Park Plaza, Suite 424</ix:nonNumeric></b></div>

			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><ix:nonNumeric contextRef="d20258K" name="dei:EntityAddressCityOrTown" id="ixv-318">Boston</ix:nonNumeric>, <ix:nonNumeric contextRef="d20258K" format="ixt-sec:stateprovnameen" name="dei:EntityAddressStateOrProvince" id="ixv-319">Massachusetts</ix:nonNumeric></b></div>
			</td>
			<td style="vertical-align:bottom;width:15.3%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><ix:nonNumeric contextRef="d20258K" name="dei:EntityAddressPostalZipCode" id="ixv-320">02116</ix:nonNumeric></b></div>
			</td>
		</tr>
		<tr>
			<td colspan="2" style="vertical-align:top;width:15.3%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>(Address of principal executive offices)</b></div>
			</td>
			<td style="vertical-align:top;width:15.3%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>(Zip Code)</b></div>
			</td>
		</tr>

</tbody></table>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Registrant</b>&#8217;<b>s telephone number, including area code: (<ix:nonNumeric contextRef="d20258K" name="dei:CityAreaCode" id="ixv-321">617</ix:nonNumeric>) <ix:nonNumeric contextRef="d20258K" name="dei:LocalPhoneNumber" id="ixv-322">744-4400</ix:nonNumeric></b></div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Not applicable</b></div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>(Former name or former address, if changed since last report)</b></div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">&#160;</div>

<hr style="text-align: center; height: 1px; color: #000000; background-color: #000000; width: 25%; border: none; margin: 3pt auto"/>
<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 18pt;">
			<div style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;"><ix:nonNumeric contextRef="d20258K" format="ixt-sec:boolballotbox" name="dei:WrittenCommunications" id="ixv-323">&#9744;</ix:nonNumeric></div>
			</td>
			<td style="width: auto;">
			<div style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</div>
			</td>
		</tr>
		<tr style="vertical-align: top;">
			<td style="width: 18pt;">&#160;</td>
			<td style="width: auto;">
			<div style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">&#160;</div>
			</td>
		</tr>
		<tr style="vertical-align: top;">
			<td style="width: 18pt;">
			<div style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;"><ix:nonNumeric contextRef="d20258K" format="ixt-sec:boolballotbox" name="dei:SolicitingMaterial" id="ixv-324">&#9744;</ix:nonNumeric></div>
			</td>
			<td style="width: auto;">
			<div style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</div>
			</td>
		</tr>
		<tr style="vertical-align: top;">
			<td style="width: 18pt;">&#160;</td>
			<td style="width: auto;">
			<div style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">&#160;</div>
			</td>
		</tr>
		<tr style="vertical-align: top;">
			<td style="width: 18pt;">
			<div style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;"><ix:nonNumeric contextRef="d20258K" format="ixt-sec:boolballotbox" name="dei:PreCommencementTenderOffer" id="ixv-325">&#9744;</ix:nonNumeric></div>
			</td>
			<td style="width: auto;">
			<div style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</div>
			</td>
		</tr>
		<tr style="vertical-align: top;">
			<td style="width: 18pt;">&#160;</td>
			<td style="width: auto;">
			<div style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">&#160;</div>
			</td>
		</tr>
		<tr style="vertical-align: top;">
			<td style="width: 18pt;">
			<div style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;"><ix:nonNumeric contextRef="d20258K" format="ixt-sec:boolballotbox" name="dei:PreCommencementIssuerTenderOffer" id="ixv-326">&#9744;</ix:nonNumeric></div>
			</td>
			<td style="width: auto;">
			<div style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</div>
			</td>
		</tr>

</tbody></table>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tbody><tr>
			<td style="border-bottom:solid 1px #000000;vertical-align:bottom;width:15.3%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Title of each class</b></div>
			</td>
			<td style="vertical-align:bottom;width:0.5%;">&#160;</td>
			<td style="border-bottom:solid 1px #000000;vertical-align:bottom;width:14.8%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Trading</b></div>

			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Symbol(s)</b></div>
			</td>
			<td style="vertical-align:bottom;width:0.5%;">&#160;</td>
			<td style="border-bottom:solid 1px #000000;vertical-align:bottom;width:15.3%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Name of each exchange</b></div>

			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>on which registered</b></div>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:15.3%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><ix:nonNumeric contextRef="d20258K" name="dei:Security12bTitle" id="ixv-327">Common Stock</ix:nonNumeric>, $0.001 par value</div>
			</td>
			<td style="vertical-align:bottom;width:0.5%;">&#160;</td>
			<td style="vertical-align:top;width:14.8%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="d20258K" name="dei:TradingSymbol" id="ixv-328">CRVO</ix:nonNumeric></div>
			</td>
			<td style="vertical-align:bottom;width:0.5%;">&#160;</td>
			<td style="vertical-align:top;width:15.3%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="d20258K" format="ixt-sec:exchnameen" name="dei:SecurityExchangeName" id="ixv-329">NASDAQ</ix:nonNumeric> Capital Market</div>
			</td>
		</tr>

</tbody></table>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (&#167;240.12b-2 of this chapter).</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Emerging growth company <ix:nonNumeric contextRef="d20258K" format="ixt-sec:boolballotbox" name="dei:EntityEmergingGrowthCompany" id="ixv-330">&#9744;</ix:nonNumeric></div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. &#9744;</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGNUM" style="text-align: center; width: 100%">&#160;</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
<div class="PGHDR" style="text-align: left; width: 100%">&#160;</div>
</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Item 7.01</b>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<b>Regulation FD Disclosure</b></div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i>Press Release</i></div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">On October 8, 2025, CervoMed Inc. (the &#8220;Company,&#8221; &#8220;we&#8221; or &#8220;us&#8221;) issued a press release announcing new data from the RewinD-LB Phase 2b clinical trial of neflamapimod in patients with dementia with Lewy bodies (&#8220;RewinD-LB Trial&#8221;). A copy of the press release is attached hereto as Exhibit 99.1 and incorporated by reference herein.</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i>Presentation</i></div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Certain information concerning the business, clinical studies, development plans, financial position and related matters of the Company, including the new results from the RewinD-LB Trial, has been made available on our website, www.cervomed.com, under the heading, &#8220;Investors &#8211; Events and Presentations.&#8221; Representatives of the Company may use this presentation, in whole or in part, and possibly with non-material modifications, periodically in connection with conferences, meetings, and presentations to investors, analysts and others.</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The information contained in the presentation is summary information that is intended to be considered in the context of the Company&#8217;s filings with the U.S. Securities and Exchange Commission (&#8220;SEC&#8221;) and other public announcements that the Company may make, by press release or otherwise, from time to time. The Company undertakes no duty or obligation to publicly update or revise the information contained in the presentation except as required by applicable law, although the Company may do so from time to time as its management believes is warranted. Any such updating may be made through the filing of other reports or documents with the SEC, through press releases, or through other public disclosure. The Company makes no admission or representation as to the materiality of any information in the presentation or otherwise contained in Item 7.01 of this Current Report on Form 8-K.</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">--</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The information in this Item 7.01 is being furnished and shall not be deemed &#8220;filed&#8221; for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;), or otherwise subject to the liabilities of that Section, nor shall it be deemed incorporated by reference into any registration statement or other filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Item 8.01</b>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<b>Other Events</b></div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The information set forth in the first paragraph and the information under the heading, &#8220;New Results from the Phase 2b RewinD-LB Trial,&#8221; of the Company&#8217;s press release referred to in Item 7.01 above is incorporated by reference into this Item 8.01 of this Current&#160;Report&#160;on&#160;Form&#160;8-K.</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 54pt;text-indent:-54pt;"><b>Item 9.01</b>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<b>Financial Statements and Exhibits</b></div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>(d)</i></b>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<b><i>Exhibits</i></b></div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tbody><tr>
			<td style="vertical-align:bottom;width:4.6%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Exhibit No.</b></div>
			</td>
			<td style="border-bottom:solid 1px #000000;vertical-align:bottom;width:41.7%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Description</b></div>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:middle;width:4.6%;">&#160;</td>
			<td style="vertical-align:middle;width:41.7%;">&#160;</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:4.6%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">99.1</div>
			</td>
			<td style="vertical-align:top;width:41.7%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="ex_867784.htm" style="-sec-extract:exhibit;">Press Release, issued October 8, 2025</a></div>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:4.6%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">104</div>
			</td>
			<td style="vertical-align:top;width:41.7%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Cover Page Interactive Data File (embedded within the Inline XBRL document).</div>
			</td>
		</tr>

</tbody></table>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGNUM" style="text-align: center; width: 100%">&#160;</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
<div class="PGHDR" style="text-align: left; width: 100%">&#160;</div>
</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>SIGNATURES</b></div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<table cellpadding="0" cellspacing="0" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 100%; margin-left: 0pt; margin-right: 0pt;">

		<tbody><tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="vertical-align: middle; width: 49%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<div style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Date: October 8, 2025</div>
			</td>
			<td colspan="2" style="vertical-align: middle; width: 4%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<div style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><b>CervoMed Inc.</b></div>
			</td>
			<td style="vertical-align: middle; width: 11%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
		</tr>
		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="vertical-align: middle; width: 49%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="vertical-align: middle; width: 4%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="vertical-align: middle; width: 36%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="vertical-align: middle; width: 11%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
		</tr>
		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="vertical-align: middle; width: 49%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="vertical-align: middle; width: 4%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<div style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">By:</div>
			</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 36%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<div style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">/s/ William Elder</div>
			</td>
			<td style="vertical-align: middle; width: 11%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
		</tr>
		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="vertical-align: middle; width: 49%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="vertical-align: middle; width: 4%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<div style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Name:</div>
			</td>
			<td style="vertical-align: middle; width: 36%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<div style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">William Elder</div>
			</td>
			<td style="vertical-align: middle; width: 11%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
		</tr>
		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="vertical-align: middle; width: 49%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="vertical-align: middle; width: 4%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<div style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Title:</div>
			</td>
			<td style="vertical-align: middle; width: 36%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<div style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Chief Financial Officer &amp; General Counsel</div>
			</td>
			<td style="vertical-align: middle; width: 11%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
		</tr>

</tbody></table>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div class="LAST-PAGE-BREAK">
<div class="PGFTR">
<div class="hf-row">
<div class="hf-cell PGNUM">&#160;</div>
</div>
</div>
</div>


</body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>ex_867784.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<html><head>
	<title>ex_867784.htm</title>

	<!-- Generated by ThunderDome Portal - 10/8/2025 6:35:22 PM --><meta charset="utf-8"><meta name="format-detection" content="telephone=no">
</head>
<body style="font-size:10pt;font-family:'Times New Roman';padding:0in .1in;">
<div contenteditable="false" data-applyto="t" data-auto-pgnum="start" data-displaynum="1" data-fontname="Times New Roman" data-fontsize="10pt" data-numstyle="a" data-prefix="" data-startnum="1" data-suffix="" data-textalign="center">&nbsp;</div>

<p style="margin: 0px 0pt; text-align: right; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt"><b>Exhibit 99.1</b></font></p>

<p style="margin: 0px 0pt; text-align: left; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><img alt="logosmlr.jpg" src="logosmlr.jpg"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>

<p style="margin: 0px 0pt; text-align: left; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:12pt;font-variant:normal;text-align:center;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:12pt;font-variant:normal;text-align:center;margin:0pt;"><b>CervoMed Announces New Data from Phase 2b Trial Demonstrating Neflamapimod's Potential as a Treatment for Dementia with Lewy Bodies</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><i>Significant improvement relative to placebo on primary outcome measure, change in Clinical Dementia Rating Sum of Boxes (CDR-SB), demonstrated in a within-subject analysis in participants with low likelihood of having Alzheimer</i>&#8217;<i>s disease (AD) co-pathology</i></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><i>Significant reduction in plasma levels of a well-established biomarker of neurodegeneration, plasma glial fibrillary acidic protein (GFAP), correlated to treatment response assessed by CDR-SB</i></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><i>CervoMed anticipates U.S. Food and Drug Administration (FDA) feedback on Phase 3 trial design in the fourth quarter of 2025</i></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>BOSTON,</b>&nbsp;<b>October 8, 2025</b> --&nbsp;CervoMed Inc.&nbsp;(NASDAQ: CRVO), a clinical stage company focused on developing treatments for age-related neurologic disorders (CervoMed or the Company), today announced additional data from its Phase 2b RewinD-LB trial, further demonstrating neflamapimod&#8217;s potential as a treatment for dementia with Lewy bodies (DLB).</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#8220;With October recognized as Lewy Body Dementia Awareness Month, we are especially proud to share these new data from our Phase 2b RewinD-LB trial,&#8221; said John Alam, M.D., Chief Executive Officer of CervoMed and Co-Principal Investigator of the RewinD-LB trial. &#8220;The significant improvements compared to placebo in change in CDR-SB observed in the within-subject comparison, along with correlated reductions in a key biomarker of neurodegeneration further strengthen our confidence in neflamapimod&#8217;s potential as a treatment for DLB. Together with other insights gained from Phase 2b, these results have enabled us to refine and optimize the design of our planned Phase 3 trial as we await FDA feedback later this quarter.&#8221;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><u>New Results from the Phase 2b RewinD-LB Trial</u></b><sup style="vertical-align:top;line-height:120%;">1</sup></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The results announced today (presentation here) are based on the final analyses of the RewinD-LB trial, conducted after the August 2025 database lock for the full 48-week trial (16 weeks placebo-controlled (Initial Phase), followed by a 32-week neflamapimod-only extension (Extension Phase)). In addition to confirming previously reported findings, today&#8217;s announcement also includes:</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width:18pt;">&nbsp;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">A subgroup analysis of participants with a low likelihood of AD co-pathology, defined by the criteria the Company expects to use in its planned Phase 3 trial in patients with DLB; and</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width:18pt;">&nbsp;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Further analyses of the RewinD-LB trial&#8217;s primary biomarker endpoint, plasma GFAP.</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<hr style="text-align: left; height: 1px; color: #000000; background-color: #000000; width: 10%; border: none; margin: 3pt auto 3pt 0">
<p style="margin: 0pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><sup style="vertical-align:top;line-height:120%;">1</sup>All analyses reported are exploratory in nature.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="1" data-prefix="" data-suffix="" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">1</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left"><img alt="logosmlr.jpg" src="logosmlr.jpg"></p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Results in Participants Whose Plasma ptau181 Levels Were Below 21 pg/mL at Screening, Indicating a Low Likelihood of AD Co-Pathology</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">To enrich enrollment for participants without AD co-pathology, only individuals with plasma ptau181 &lt;27.2 pg/mL<sup style="vertical-align:top;line-height:120%;">2</sup> were randomized in the RewinD-LB trial. Based on the limited data available at the time the trial was designed, this 27.2 pg/mL threshold was estimated to be an appropriate cut-off for distinguishing patients with AD co-pathology from those without.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Recently, however, the first large, international multicenter study (n=1298) of the diagnostic performance of plasma ptau181 along the continuum of AD and non-AD dementias<sup style="vertical-align:top;line-height:120%;">3</sup> identified a lower threshold &#8211; 21 pg/mL &#8211; as the high-sensitivity cutoff for detecting AD pathology. Based on this progress in understanding of using ptau181 to detect AD pathology and the Company&#8217;s belief that neflamapimod is most effective as a treatment for the roughly 50% of DLB patients who do not have AD co-pathology, the statistical analysis plan for the RewinD-LB trial was amended in February 2025 to include sensitivity analyses using the &lt;21 pg/mL cutoff, which are now being reported.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">In the subset of participants whose plasma ptau181 levels were below 21 pg/mL at screening, results include:</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width:18pt;">&nbsp;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i>Initial Phase</i>: On the primary endpoint of change in CDR-SB over 16 weeks, there was a trend toward NFMD/A (Drug product batch that did not achieve targeted plasma drug concentrations, &#8220;old capsules&#8221;)<sup style="vertical-align:top;line-height:120%;">4</sup> relative to placebo (difference &#8722;0.53, p=0.10, linear mixed-effects model) during the Initial Phase of the trial.</p>
			</td>
		</tr>

</table>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width:18pt;">&nbsp;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i>Extension Phase (First 16 Weeks)</i>: NFMD/B (drug product batch that achieved plasma drug concentrations, &#8220;new capsules&#8221;)<sup style="vertical-align:top;line-height:120%;">4</sup>&nbsp;demonstrated significant improvement versus NFMD/A on CDR-SB (&#8722;0.58, p=0.024), as well on the ADCS-CGIC, Dementia-Cognitive Fluctuations Scale, and International Shopping List Test-Recognition, over the first 16 weeks of the Extension Phase.</p>
			</td>
		</tr>

</table>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width:18pt;">&nbsp;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>Within-Subject Comparison to Placebo</i></b><b>:</b>&nbsp;Participants who transitioned from placebo in the Initial Phase to NFMD/B in the Extension Phase showed significant improvement on change in CDR-SB (difference= -1.12, p=0.005) and on ADCS-CGIC (difference=&#8211;0.82, p=0.004) while they were on NFMD/B relative to when on placebo over the respective 16-week periods.</p>
			</td>
		</tr>

</table>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width:18pt;">&nbsp;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>Time-to-Progression Analysis</i></b><b>:</b>&nbsp;NFMD/B reduced the risk of clinically meaningful progression (&#8805;1.5-point CDR-SB increase) by 67% versus NFMD/A over 32 weeks (p&lt;0.001) and by 75% versus placebo over 16 weeks (p&lt;0.001).</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<hr style="text-align: left; height: 1px; color: #000000; background-color: #000000; width: 10%; border: none; margin: 3pt auto 3pt 0">
<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;"><sup style="vertical-align:top;line-height:120%;">2</sup>&nbsp;The Company has historically reported plasma ptau181 levels based on the scale associated with the Quanterix Simoa ptau181 Advantage v2.0 assay kit. In this press release and going forward, the Company will report plasma ptau181 levels based on the scale associated with the current Quanterix Simoa ptau181 Advantage v2.1 assay kit, which was utilized in the RewinD-LB trial. Quantitative values on the v2.1 scale are approximately ten-fold higher than the corresponding values on the v2.0 scale.</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;"><sup style="vertical-align:top;line-height:120%;">3</sup> <i>Alzheimer</i>&#8217;<i>s &amp; Dement.</i> 2025 Jun 23;21(6):e14573. doi: 10.1002/alz.14573</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;"><sup style="vertical-align:top;line-height:120%;">4</sup>&nbsp;In the RewinD-LB trial, two different batches of drug product were administered.&nbsp; One batch of capsules, utilized in placebo-controlled phase and initially during the extension &#8211; which we refer to as NFMD/A or the &#8220;Old Capsules&#8221; &#8211; did not achieve expected and targeted average plasma drug concentrations. The other batch of capsules, introduced during the extension &#8211; which we refer to as NFMD/B or the &#8220;New Capsules&#8221; &#8211; achieved the targeted average plasma drug concentrations.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="2" data-prefix="" data-suffix="" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">2</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left"><img alt="logosmlr.jpg" src="logosmlr.jpg"></p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>New Analyses of Neflamapimod</b>&#8217;<b>s Effect on Plasma GFAP, a Well-Established Biomarker of Neurodegenerative Disease Progression</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">In August 2025, CervoMed reported that, during the Extension Phase, neflamapimod significantly reduced plasma GFAP levels, the primary biomarker endpoint, in participants who had received 12 or more weeks of NMFD/B. This effect was not observed in participants who only received NMFD/A.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The new plasma GFAP analyses in the subset of participants whose plasma ptau181 levels were below 21 pg/mL at screening are summarized below:</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width:18pt;">&nbsp;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>Within-Subject Comparison to Placebo</i></b><b>:</b>&nbsp;Among participants who received placebo during the Initial Phase and then transitioned to NMFD/B in the Extension Phase, the change in plasma GFAP over 32 weeks of NMFD/B treatment was significantly lower than the change observed over 16 weeks of placebo treatment in the same individuals (&#8722;16.7 pg/mL with NMFD/B vs. +5.8 pg/mL with placebo; median difference &#8722;23.1 pg/mL, p=0.016, paired Wilcoxon test). This represents an estimated 50% reduction in disease-specific elevation in plasma GFAP levels<sup style="vertical-align:top;line-height:120%;">5</sup>.</p>
			</td>
		</tr>

</table>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width:18pt;">&nbsp;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>Correlation with Clinical Outcomes</i></b><b>:</b>&nbsp;During the Extension Phase, in participants with a low likelihood of AD co-pathology, plasma GFAP change significantly correlated with CDR-SB change (p=0.036). Specifically, reductions in plasma GFAP were associated with improvements in CDR-SB scores (lower dementia severity), whereas increases in plasma GFAP corresponded to worsening scores. These findings directly correlate the biomarker effect to a clinically meaningful treatment response.</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>About the RewinD-LB Phase 2b Trial in Dementia with Lewy Bodies</b><br>
The initial phase of RewinD-LB was a randomized, 16-week, double-blind, placebo-controlled clinical trial evaluating oral neflamapimod (40mg TID) in 159 participants with DLB, followed by a 32-week neflamapimod-only treatment Extension phase. Patients with AD co-pathology, as assessed by plasma ptau181 levels, were excluded from the trial. Compared to patients with &#8220;pure&#8221; DLB &#8211; who may comprise up to 50% of the total diagnosed DLB patient population at any given time &#8211; DLB patients with AD co-pathology have significant, irreversible neuronal loss in the hippocampus that limits response to treatment. The primary endpoint in the trial is change in the CDR-SB, and secondary endpoints include the ADCS-CGIC, the Timed Up and Go test, and a cognitive test battery. The RewinD-LB trial was funded primarily by a&nbsp;$21.3 million&nbsp;grant from the&nbsp;National Institutes&nbsp;of Health&#8217;s&nbsp;National Institute on Aging, disbursed over the course of the trial as costs were incurred. The trial included 43 sites across in&nbsp;the United States, the&nbsp;United Kingdom, and&nbsp;the Netherlands. The initial phase of the study did not effectively evaluate the clinical activity of 40mg TID neflamapimod compared to placebo because the batch of neflamapimod capsules utilized during the placebo-controlled phase of the study did not lead to the average plasma drug concentrations expected with such a dose. However, in the Extension phase, a portion of participants were administered a more recently manufactured batch of capsules that achieved targeted average plasma drug concentrations, allowing the effects of 40 mg TID neflamapimod treatment to be effectively evaluated during the Extension phase, with participants receiving the newer capsules serving as an active drug arm. Outcomes in these participants were compared with those in the subset of participants who continued to receive the older batch of capsules during the Extension phase, which served as a control arm.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<hr style="text-align: left; height: 1px; color: #000000; background-color: #000000; width: 10%; border: none; margin: 3pt auto 3pt 0">
<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;"><sup style="vertical-align:top;line-height:120%;">5</sup>&nbsp;Based on mean ~150 pg/mL in participants with DLB vs. ~100 pg/mL in healthy controls; Doecke et al., 2025.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="3" data-prefix="" data-suffix="" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">3</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left"><img alt="logosmlr.jpg" src="logosmlr.jpg"></p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>About CervoMed</b><br>
CervoMed is a clinical-stage company focused on developing treatments for age-related neurologic disorders. The Company is currently developing neflamapimod, an investigational, orally administered small molecule brain penetrant that inhibits p38 mitogen-activated protein kinase alpha. Neflamapimod has the potential to treat synaptic dysfunction, the reversible aspect of the underlying neurodegenerative processes that cause disease in DLB and certain other major neurological disorders. The Company&#8217;s recently completed Phase 2b trial evaluated neflamapimod in patients with DLB.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Forward-Looking Statements</b><br>
This press release includes express and implied forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, regarding the intentions, plans, beliefs, expectations or forecasts for the future of the Company, including, but not limited to: the therapeutic potential of neflamapimod, including the degree of sustainability of any therapeutic effects; the anticipated timing and achievement of clinical and development milestones, including the Company&#8217;s announcement of additional data, if any, from the RewinD-LB Phase 2b clinical trial and any meeting or correspondence between the Company and the FDA; any other expected or implied benefits or results, including that any initial clinical results observed with respect to neflamapimod in the RewinD-LB trial will be replicated in later trials; and the timing of the initiation of any potential future trials or interactions with regulatory authorities, including the Company&#8217;s need to acquire sufficient funding for any Phase 3 trial of neflamapimod in DLB. Terms such as &#8220;believes,&#8221; &#8220;estimates,&#8221; &#8220;anticipates,&#8221; &#8220;expects,&#8221; &#8220;plans,&#8221; &#8220;aims,&#8221; &#8220;seeks,&#8221; &#8220;intends,&#8221; &#8220;may,&#8221; &#8220;might,&#8221; &#8220;could,&#8221; &#8220;might,&#8221; &#8220;will,&#8221; &#8220;should,&#8221; &#8220;approximately,&#8221; &#8220;potential,&#8221; &#8220;target,&#8221; &#8220;project,&#8221; &#8220;contemplate,&#8221; &#8220;predict,&#8221; &#8220;forecast,&#8221; &#8220;continue,&#8221; or other words that convey uncertainty of future events or outcomes (including the negative of these terms) may identify these forward-looking statements. Although there is believed to be reasonable basis for each forward-looking statement contained herein, forward-looking statements by their nature involve risks and uncertainties, known and unknown, many of which are beyond the Company&#8217;s control and, as a result, actual results could differ materially from those expressed or implied in any forward-looking statement. Particular risks and uncertainties include, among other things, those related to: the Company&#8217;s available cash resources and the availability of additional funds on acceptable terms; the results of the Company&#8217;s clinical trials, including RewinD-LB; the likelihood and timing of any regulatory approval of neflamapimod or the nature of any feedback the Company may receive from the FDA; the ability to implement business plans, forecasts, and other expectations in the future; general economic, political, business, industry, and market conditions, inflationary pressures, and geopolitical conflicts; and the other factors discussed under the heading &#8220;Risk Factors&#8221; in the Company&#8217;s Annual Report on Form 10-K for the year ended December 31, 2024 filed with the U.S. Securities and Exchange Commission (SEC) on March 17, 2025, and other filings that the Company may file from time to time with the SEC. Any forward-looking statements in this press release speak only as of the date hereof (or such earlier date as may be identified). The Company does not undertake any obligation to update such forward-looking statements to reflect events or circumstances after the date of this press release, except to the extent required by law.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Contacts</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Investors:</b><br>
PJ Kelleher<br>
LifeSci Advisors<br>
<u>Investors@cervomed.com</u><br>
617-430-7579</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Media:</b><br>
Argot Partners<br>
<u>liza@argotpartners.com</u><br>
212-600-1902</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="LAST-PAGE-BREAK">
<div class="PGFTR">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="4" data-prefix="" data-suffix="" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">4</div>
</div>
</div>
</div>


</body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>3
<FILENAME>crvo-20251008.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
<!--Generated by ThunderDome Portal - 10/8/2025 6:57:00 PM-->
<xsd:schema xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xsd="http://www.w3.org/2001/XMLSchema" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:stpr="http://xbrl.sec.gov/stpr/2024" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:dei="http://xbrl.sec.gov/dei/2024" xmlns:country="http://xbrl.sec.gov/country/2024" xmlns:sic="http://xbrl.sec.gov/sic/2024" xmlns:currency="http://xbrl.sec.gov/currency/2024" xmlns:exch="http://xbrl.sec.gov/exch/2024" xmlns:cyd="http://xbrl.sec.gov/cyd/2024" xmlns:crvo="http://www.crvo.com/20251008" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.crvo.com/20251008">
<xsd:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
<xsd:import namespace="http://www.xbrl.org/2009/role/negated" schemaLocation="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd"/>
<xsd:import namespace="http://xbrl.sec.gov/stpr/2024" schemaLocation="https://xbrl.sec.gov/stpr/2024/stpr-2024.xsd"/>
<xsd:import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd"/>
<xsd:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd"/>
<xsd:import namespace="http://xbrl.sec.gov/dei/2024" schemaLocation="https://xbrl.sec.gov/dei/2024/dei-2024.xsd"/>
<xsd:import namespace="http://xbrl.sec.gov/country/2024" schemaLocation="https://xbrl.sec.gov/country/2024/country-2024.xsd"/>
<xsd:import namespace="http://xbrl.sec.gov/sic/2024" schemaLocation="https://xbrl.sec.gov/sic/2024/sic-2024.xsd"/>
<xsd:import namespace="http://xbrl.sec.gov/currency/2024" schemaLocation="https://xbrl.sec.gov/currency/2024/currency-2024.xsd"/>
<xsd:import namespace="http://xbrl.sec.gov/exch/2024" schemaLocation="https://xbrl.sec.gov/exch/2024/exch-2024.xsd"/>
<xsd:import namespace="http://xbrl.sec.gov/cyd-8k-sub/2024" schemaLocation="https://xbrl.sec.gov/cyd/2024/cyd-8k-sub-2024.xsd"/>

<xsd:annotation>
<xsd:appinfo>
<link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="crvo-20251008_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
<link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="crvo-20251008_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"/>
<link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="crvo-20251008_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
<link:roleType id="statement-document-and-entity-information" roleURI="http://www.crvo.com/20251008/role/statement-document-and-entity-information">
<link:definition xmlns="http://www.xbrl.org/2003/linkbase">000 - Document - Document And Entity Information</link:definition>
<link:usedOn>link:calculationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:presentationLink</link:usedOn>
</link:roleType>
</xsd:appinfo>
</xsd:annotation>
<xsd:element abstract="true" id="crvo_DocumentAndEntityInformation" name="DocumentAndEntityInformation" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>4
<FILENAME>crvo-20251008_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
<!--Generated by ThunderDome Portal - 10/8/2025 6:57:00 PM-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
<link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" xlink:type="simple"/>
<link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" xlink:type="simple"/>
<link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" xlink:type="simple"/>
<link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" xlink:type="simple"/>
<link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" xlink:type="simple"/>
<link:roleRef roleURI="http://www.crvo.com/20251008/role/statement-document-and-entity-information" xlink:href="crvo-20251008.xsd#statement-document-and-entity-information" xlink:type="simple"/>
<link:definitionLink xlink:role="http://www.crvo.com/20251008/role/statement-document-and-entity-information" xlink:type="extended">
<link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentInformationTable" xlink:label="dei_DocumentInformationTable" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentInformationLineItems" xlink:label="dei_DocumentInformationLineItems" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType" xlink:label="dei_DocumentType" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" xlink:type="locator"/>
<link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
<link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>

<link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="dei_DocumentInformationTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>


<link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentInformationTable" xlink:type="arc"/>
<link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentType" xlink:type="arc"/>
<link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentPeriodEndDate" xlink:type="arc"/>
<link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityRegistrantName" xlink:type="arc"/>
<link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityIncorporationStateCountryCode" xlink:type="arc"/>
<link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityFileNumber" xlink:type="arc"/>
<link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityTaxIdentificationNumber" xlink:type="arc"/>
<link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressAddressLine1" xlink:type="arc"/>
<link:definitionArc order="8" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressCityOrTown" xlink:type="arc"/>
<link:definitionArc order="9" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressStateOrProvince" xlink:type="arc"/>
<link:definitionArc order="10" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressPostalZipCode" xlink:type="arc"/>
<link:definitionArc order="11" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_CityAreaCode" xlink:type="arc"/>
<link:definitionArc order="12" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_LocalPhoneNumber" xlink:type="arc"/>
<link:definitionArc order="13" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_WrittenCommunications" xlink:type="arc"/>
<link:definitionArc order="14" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_SolicitingMaterial" xlink:type="arc"/>
<link:definitionArc order="15" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_PreCommencementTenderOffer" xlink:type="arc"/>
<link:definitionArc order="16" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_PreCommencementIssuerTenderOffer" xlink:type="arc"/>
<link:definitionArc order="17" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_Security12bTitle" xlink:type="arc"/>
<link:definitionArc order="18" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_TradingSymbol" xlink:type="arc"/>
<link:definitionArc order="19" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_SecurityExchangeName" xlink:type="arc"/>
<link:definitionArc order="20" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityEmergingGrowthCompany" xlink:type="arc"/>
<link:definitionArc order="21" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AmendmentFlag" xlink:type="arc"/>
<link:definitionArc order="22" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCentralIndexKey" xlink:type="arc"/>

</link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>5
<FILENAME>crvo-20251008_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
<!--Generated by ThunderDome Portal - 10/8/2025 6:57:00 PM-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
<link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" xlink:type="simple"/>
<link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" xlink:type="simple"/>
<link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" xlink:type="simple"/>
<link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" xlink:type="simple"/>
<link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" xlink:type="simple"/>
<link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" xlink:type="simple"/>
<link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" xlink:type="simple"/>
<link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
<link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
<link:label xlink:label="dei_EntityDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity [Domain]</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityDomain" xlink:to="dei_EntityDomain-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
<link:label xlink:label="dei_LegalEntityAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Legal Entity [Axis]</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LegalEntityAxis" xlink:to="dei_LegalEntityAxis-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentInformationLineItems" xlink:label="dei_DocumentInformationLineItems" xlink:type="locator"/>
<link:label xlink:label="dei_DocumentInformationLineItems-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Information [Line Items]</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentInformationLineItems-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentInformationTable" xlink:label="dei_DocumentInformationTable" xlink:type="locator"/>
<link:label xlink:label="dei_DocumentInformationTable-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Information [Table]</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentInformationTable" xlink:to="dei_DocumentInformationTable-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType" xlink:label="dei_DocumentType" xlink:type="locator"/>
<link:label xlink:label="dei_DocumentType-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document, Type</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" xlink:type="locator"/>
<link:label xlink:label="dei_DocumentPeriodEndDate-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document, Period End Date</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" xlink:type="locator"/>
<link:label xlink:label="dei_EntityRegistrantName-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity, Registrant Name</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" xlink:type="locator"/>
<link:label xlink:label="dei_EntityIncorporationStateCountryCode-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity, Incorporation, State or Country Code</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" xlink:type="locator"/>
<link:label xlink:label="dei_EntityFileNumber-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity, File Number</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" xlink:type="locator"/>
<link:label xlink:label="dei_EntityTaxIdentificationNumber-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity, Tax Identification Number</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" xlink:type="locator"/>
<link:label xlink:label="dei_EntityAddressAddressLine1-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity, Address, Address Line One</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" xlink:type="locator"/>
<link:label xlink:label="dei_EntityAddressCityOrTown-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity, Address, City or Town</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" xlink:type="locator"/>
<link:label xlink:label="dei_EntityAddressStateOrProvince-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity, Address, State or Province</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" xlink:type="locator"/>
<link:label xlink:label="dei_EntityAddressPostalZipCode-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity, Address, Postal Zip Code</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" xlink:type="locator"/>
<link:label xlink:label="dei_CityAreaCode-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">City Area Code</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" xlink:type="locator"/>
<link:label xlink:label="dei_LocalPhoneNumber-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Local Phone Number</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications" xlink:type="locator"/>
<link:label xlink:label="dei_WrittenCommunications-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Written Communications</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial" xlink:type="locator"/>
<link:label xlink:label="dei_SolicitingMaterial-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Soliciting Material</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer" xlink:type="locator"/>
<link:label xlink:label="dei_PreCommencementTenderOffer-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer" xlink:type="locator"/>
<link:label xlink:label="dei_PreCommencementIssuerTenderOffer-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" xlink:type="locator"/>
<link:label xlink:label="dei_Security12bTitle-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Title of 12(b) Security</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" xlink:type="locator"/>
<link:label xlink:label="dei_TradingSymbol-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Symbol</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" xlink:type="locator"/>
<link:label xlink:label="dei_SecurityExchangeName-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Security Exchange Name</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" xlink:type="locator"/>
<link:label xlink:label="dei_EntityEmergingGrowthCompany-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity, Emerging Growth Company</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" xlink:type="locator"/>
<link:label xlink:label="dei_AmendmentFlag-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amendment Flag</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" xlink:type="locator"/>
<link:label xlink:label="dei_EntityCentralIndexKey-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity, Central Index Key</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey-label" xlink:type="arc"/>

</link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>6
<FILENAME>crvo-20251008_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
<!--Generated by ThunderDome Portal - 10/8/2025 6:57:00 PM-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
<link:roleRef roleURI="http://www.crvo.com/20251008/role/statement-document-and-entity-information" xlink:href="crvo-20251008.xsd#statement-document-and-entity-information" xlink:type="simple"/>
<link:presentationLink xlink:role="http://www.crvo.com/20251008/role/statement-document-and-entity-information" xlink:type="extended">
<link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentInformationTable" xlink:label="dei_DocumentInformationTable" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentInformationLineItems" xlink:label="dei_DocumentInformationLineItems" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType" xlink:label="dei_DocumentType" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" xlink:type="locator"/>
<link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>

<link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>

<link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationTable" xlink:to="dei_DocumentInformationLineItems" xlink:type="arc"/>
<link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityRegistrantName" xlink:type="arc"/>
<link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentType" xlink:type="arc"/>
<link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentPeriodEndDate" xlink:type="arc"/>
<link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityIncorporationStateCountryCode" xlink:type="arc"/>
<link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityFileNumber" xlink:type="arc"/>
<link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityTaxIdentificationNumber" xlink:type="arc"/>
<link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressAddressLine1" xlink:type="arc"/>
<link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressCityOrTown" xlink:type="arc"/>
<link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressStateOrProvince" xlink:type="arc"/>
<link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressPostalZipCode" xlink:type="arc"/>
<link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_CityAreaCode" xlink:type="arc"/>
<link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_LocalPhoneNumber" xlink:type="arc"/>
<link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_WrittenCommunications" xlink:type="arc"/>
<link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_SolicitingMaterial" xlink:type="arc"/>
<link:presentationArc order="14" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_PreCommencementTenderOffer" xlink:type="arc"/>
<link:presentationArc order="15" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_PreCommencementIssuerTenderOffer" xlink:type="arc"/>
<link:presentationArc order="16" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_Security12bTitle" xlink:type="arc"/>
<link:presentationArc order="17" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_TradingSymbol" xlink:type="arc"/>
<link:presentationArc order="18" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_SecurityExchangeName" xlink:type="arc"/>
<link:presentationArc order="19" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityEmergingGrowthCompany" xlink:type="arc"/>
<link:presentationArc order="20" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AmendmentFlag" xlink:type="arc"/>
<link:presentationArc order="21" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCentralIndexKey" xlink:type="arc"/>

</link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>7
<FILENAME>logosmlr.jpg
<TEXT>
begin 644 logosmlr.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_X0 L17AI9@  34T *@    @  0$Q  (
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M<9_"O0-(U6VUK1+35+1@;>ZA69#GH",X/TK.25DT6F[V9SGBSQ;?:9XL\/\
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44 %%%% !1110 4444 %%%% '_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>9
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Document And Entity Information<br></strong></div></th>
<th class="th"><div>Oct. 08, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity, Registrant Name</a></td>
<td class="text">CervoMed Inc.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document, Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document, Period End Date</a></td>
<td class="text">Oct.  08,  2025<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity, Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity, File Number</a></td>
<td class="text">001-37942<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity, Tax Identification Number</a></td>
<td class="text">30-0645032<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity, Address, Address Line One</a></td>
<td class="text">20 Park Plaza, Suite 424<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity, Address, City or Town</a></td>
<td class="text">Boston<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity, Address, State or Province</a></td>
<td class="text">MA<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity, Address, Postal Zip Code</a></td>
<td class="text">02116<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">617<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">744-4400<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">CRVO<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity, Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity, Central Index Key</a></td>
<td class="text">0001053691<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14a<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
.report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

.report table.authRefData a {
	display: block;
	font-weight: bold;
}

.report table.authRefData p {
	margin-top: 0px;
}

.report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

.report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

.report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

.report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
.pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
.report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

.report hr {
	border: 1px solid #acf;
}

/* Top labels */
.report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

.report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

.report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

.report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

.report td.pl div.a {
	width: 200px;
}

.report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
.report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
.report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
.report .re, .report .reu {
	background-color: #def;
}

.report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
.report .ro, .report .rou {
	background-color: white;
}

.report .rou td {
	border-bottom: 1px solid black;
}

.report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
.report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
.report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

.report .nump {
	padding-left: 2em;
}

.report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
.report .text {
	text-align: left;
	white-space: normal;
}

.report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

.report .text .more {
	display: none;
}

.report .text .note {
	font-style: italic;
	font-weight: bold;
}

.report .text .small {
	width: 10em;
}

.report sup {
	font-style: italic;
}

.report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.25.2</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>22</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="crvo20251008_8k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>000 - Document - Document And Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.crvo.com/20251008/role/statement-document-and-entity-information</Role>
      <ShortName>Document And Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File>crvo-20251008.xsd</File>
    <File>crvo-20251008_def.xml</File>
    <File>crvo-20251008_lab.xml</File>
    <File>crvo-20251008_pre.xml</File>
    <File doctype="8-K" isOnlyDei="true" original="crvo20251008_8k.htm">crvo20251008_8k.htm</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="22">http://xbrl.sec.gov/dei/2024</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>15
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "crvo20251008_8k.htm": {
   "nsprefix": "crvo",
   "nsuri": "http://www.crvo.com/20251008",
   "dts": {
    "schema": {
     "local": [
      "crvo-20251008.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.sec.gov/country/2024/country-2024.xsd",
      "https://xbrl.sec.gov/currency/2024/currency-2024.xsd",
      "https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd",
      "https://xbrl.sec.gov/cyd/2024/cyd-8k-sub-2024.xsd",
      "https://xbrl.sec.gov/cyd/2024/cyd-cr-2024.xsd",
      "https://xbrl.sec.gov/dei/2024/dei-2024.xsd",
      "https://xbrl.sec.gov/exch/2024/exch-2024.xsd",
      "https://xbrl.sec.gov/sic/2024/sic-2024.xsd",
      "https://xbrl.sec.gov/stpr/2024/stpr-2024.xsd"
     ]
    },
    "definitionLink": {
     "local": [
      "crvo-20251008_def.xml"
     ]
    },
    "labelLink": {
     "local": [
      "crvo-20251008_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "crvo-20251008_pre.xml"
     ]
    },
    "inline": {
     "local": [
      "crvo20251008_8k.htm"
     ]
    }
   },
   "keyStandard": 22,
   "keyCustom": 0,
   "axisStandard": 0,
   "axisCustom": 0,
   "memberStandard": 0,
   "memberCustom": 0,
   "hidden": {
    "total": 2,
    "http://xbrl.sec.gov/dei/2024": 2
   },
   "contextCount": 1,
   "entityCount": 1,
   "segmentCount": 0,
   "elementCount": 36,
   "unitCount": 0,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/dei/2024": 22
   },
   "report": {
    "R1": {
     "role": "http://www.crvo.com/20251008/role/statement-document-and-entity-information",
     "longName": "000 - Document - Document And Entity Information",
     "shortName": "Document And Entity Information",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "d20258K",
      "name": "dei:EntityRegistrantName",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "b",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "crvo20251008_8k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "d20258K",
      "name": "dei:EntityRegistrantName",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "b",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "crvo20251008_8k.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://www.crvo.com/20251008/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CityAreaCode",
     "presentation": [
      "http://www.crvo.com/20251008/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentInformationLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentInformationLineItems",
     "presentation": [
      "http://www.crvo.com/20251008/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Information [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentInformationTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentInformationTable",
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Information [Table]",
        "documentation": "Container to support the formal attachment of each official or unofficial, public or private document as part of a submission package."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://www.crvo.com/20251008/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document, Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentType",
     "presentation": [
      "http://www.crvo.com/20251008/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document, Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://www.crvo.com/20251008/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity, Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://www.crvo.com/20251008/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity, Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://www.crvo.com/20251008/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity, Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://www.crvo.com/20251008/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity, Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://www.crvo.com/20251008/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity, Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityDomain",
     "presentation": [
      "http://www.crvo.com/20251008/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity [Domain]",
        "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://www.crvo.com/20251008/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity, Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://www.crvo.com/20251008/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity, File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://www.crvo.com/20251008/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity, Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://www.crvo.com/20251008/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity, Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://www.crvo.com/20251008/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity, Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_LegalEntityAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "LegalEntityAxis",
     "presentation": [
      "http://www.crvo.com/20251008/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Legal Entity [Axis]",
        "documentation": "The set of legal entities associated with a report."
       }
      }
     },
     "auth_ref": []
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://www.crvo.com/20251008/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "cyd_MaterialCybersecurityIncidentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "MaterialCybersecurityIncidentAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Material Cybersecurity Incident [Abstract]"
       }
      }
     },
     "auth_ref": [
      "r6",
      "r7"
     ]
    },
    "cyd_MaterialCybersecurityIncidentAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "MaterialCybersecurityIncidentAxis",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/MaterialCybersecurityIncidentDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Material Cybersecurity Incident [Axis]"
       }
      }
     },
     "auth_ref": [
      "r6",
      "r7"
     ]
    },
    "cyd_MaterialCybersecurityIncidentDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "MaterialCybersecurityIncidentDomain",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/MaterialCybersecurityIncidentDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Material Cybersecurity Incident [Domain]"
       }
      }
     },
     "auth_ref": [
      "r6",
      "r7"
     ]
    },
    "cyd_MaterialCybersecurityIncidentInformationNotAvailableOrUndeterminedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "MaterialCybersecurityIncidentInformationNotAvailableOrUndeterminedTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/MaterialCybersecurityIncidentDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Material Cybersecurity Incident Information Not Available or Undetermined [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r6",
      "r8"
     ]
    },
    "cyd_MaterialCybersecurityIncidentLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "MaterialCybersecurityIncidentLineItems",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/MaterialCybersecurityIncidentDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Material Cybersecurity Incident [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r6",
      "r9"
     ]
    },
    "cyd_MaterialCybersecurityIncidentMaterialImpactOrReasonablyLikelyMaterialImpactTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "MaterialCybersecurityIncidentMaterialImpactOrReasonablyLikelyMaterialImpactTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/MaterialCybersecurityIncidentDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Material Cybersecurity Incident Material Impact or Reasonably Likely Material Impact [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r6",
      "r9"
     ]
    },
    "cyd_MaterialCybersecurityIncidentNatureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "MaterialCybersecurityIncidentNatureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/MaterialCybersecurityIncidentDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Material Cybersecurity Incident Nature [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r6",
      "r9"
     ]
    },
    "cyd_MaterialCybersecurityIncidentScopeTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "MaterialCybersecurityIncidentScopeTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/MaterialCybersecurityIncidentDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Material Cybersecurity Incident Scope [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r6",
      "r9"
     ]
    },
    "cyd_MaterialCybersecurityIncidentTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "MaterialCybersecurityIncidentTable",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/MaterialCybersecurityIncidentDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Material Cybersecurity Incident [Table]"
       }
      }
     },
     "auth_ref": [
      "r6",
      "r7"
     ]
    },
    "cyd_MaterialCybersecurityIncidentTimingTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "MaterialCybersecurityIncidentTimingTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/MaterialCybersecurityIncidentDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Material Cybersecurity Incident Timing [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r6",
      "r9"
     ]
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "PreCommencementIssuerTenderOffer",
     "presentation": [
      "http://www.crvo.com/20251008/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Issuer Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "dei_PreCommencementTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "PreCommencementTenderOffer",
     "presentation": [
      "http://www.crvo.com/20251008/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "Security12bTitle",
     "presentation": [
      "http://www.crvo.com/20251008/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r0"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://www.crvo.com/20251008/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_SolicitingMaterial": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "SolicitingMaterial",
     "presentation": [
      "http://www.crvo.com/20251008/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Soliciting Material",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "TradingSymbol",
     "presentation": [
      "http://www.crvo.com/20251008/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "dei_WrittenCommunications": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "WrittenCommunications",
     "presentation": [
      "http://www.crvo.com/20251008/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Written Communications",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act."
       }
      }
     },
     "auth_ref": [
      "r10"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r1": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r2": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r3": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r4": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14a",
   "Subsection": "12"
  },
  "r5": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r6": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 6-K",
   "Section": "General Instruction",
   "Subsection": "B"
  },
  "r7": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 8-K",
   "Section": "1.05"
  },
  "r8": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 8-K",
   "Section": "1.05",
   "Subsection": "Instruction",
   "Paragraph": "2"
  },
  "r9": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 8-K",
   "Section": "1.05",
   "Subsection": "a"
  },
  "r10": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "425"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>16
<FILENAME>0001437749-25-030719-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001437749-25-030719-xbrl.zip
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MNNQGM$CQ(D%<PP5ODA%*Z[/AA963>!1;-\N?2/;_J>*7_P!02P,$%     @
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M-%;A2U#J)Q'SP]/>,;F;D[ ?NC'Z(,:]RGP#!WR#EO6M[!2\B^5?5RSO;^+
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MA.:=?E/1"=E?=A5F13N[2L S/GKIS)=,*.Y2/Q$ %4;I#!NU]=_T]]#_!;L
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M2TP/$9,=7I@T+:50X9<$??S+S)W_!U!+ P04    "  NA$A;R:G(E/09  "
M<@  #0   &5X7S@V-S<X-"YH=&WM75M3&TF6?I[^%;G,3C?$2K(DC,$($R/
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M)E*5F)0F"(H08&6]J2YU2$%>UALRLJ07@RB',!]^02YBK QFFOR,%UO]+1'
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MG[Z+ HL78D5N33DU"JT8ON"01+I*()Z)3!>]TCWT5"=X9(6R)9/Y_+2QZM-
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MOSSY_U!+ 0(4 Q0    ( "Z$2%M0-8=]?P,  !D.   1              "
M 0    !C<G9O+3(P,C4Q,# X+GAS9%!+ 0(4 Q0    ( "Z$2%M1X!_GV00
M .4L   5              "  :X#  !C<G9O+3(P,C4Q,# X7V1E9BYX;6Q0
M2P$"% ,4    "  NA$A;T6^X./H%  !#/   %0              @ &Z"
M8W)V;RTR,#(U,3 P.%]L86(N>&UL4$L! A0#%     @ +H1(6XN'7I=V!
M?2T  !4              ( !YPX  &-R=F\M,C R-3$P,#A?<')E+GAM;%!+
M 0(4 Q0    ( "Z$2%M6$9QTIQ(  'Z    3              "  9 3  !C
M<G9O,C R-3$P,#A?.&LN:'1M4$L! A0#%     @ +H1(6\FIR)3T&0  @'(
M  T              ( !:"8  &5X7S@V-S<X-"YH=&U02P4&      8 !@"$
) 0  AT

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>crvo20251008_8k_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2024"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="crvo-20251008.xsd" xlink:type="simple"/>
    <context id="d20258K">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001053691</identifier>
        </entity>
        <period>
            <startDate>2025-10-08</startDate>
            <endDate>2025-10-08</endDate>
        </period>
    </context>
    <dei:AmendmentFlag contextRef="d20258K" id="ixv-300">false</dei:AmendmentFlag>
    <dei:EntityCentralIndexKey contextRef="d20258K" id="ixv-301">0001053691</dei:EntityCentralIndexKey>
    <dei:DocumentType contextRef="d20258K" id="ixv-311">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate contextRef="d20258K" id="ixv-312">2025-10-08</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName contextRef="d20258K" id="ixv-313">CervoMed Inc.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="d20258K" id="ixv-314">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber contextRef="d20258K" id="ixv-315">001-37942</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber contextRef="d20258K" id="ixv-316">30-0645032</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="d20258K" id="ixv-317">20 Park Plaza, Suite 424</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown contextRef="d20258K" id="ixv-318">Boston</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="d20258K" id="ixv-319">MA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="d20258K" id="ixv-320">02116</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="d20258K" id="ixv-321">617</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="d20258K" id="ixv-322">744-4400</dei:LocalPhoneNumber>
    <dei:WrittenCommunications contextRef="d20258K" id="ixv-323">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial contextRef="d20258K" id="ixv-324">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer contextRef="d20258K" id="ixv-325">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer contextRef="d20258K" id="ixv-326">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle contextRef="d20258K" id="ixv-327">Common Stock</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="d20258K" id="ixv-328">CRVO</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="d20258K" id="ixv-329">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany contextRef="d20258K" id="ixv-330">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
